Vesta Medical VestaBlate uterine balloon system begins U.S. clinicals.
This article was originally published in The Gray Sheet
VESTA MEDICAL VESTABLATE UTERINE BALLOON SYSTEM U.S. CLINICALS begin with first treatment Jan. 31, the Mountain View, California-based firm reports. Under an investigational device exemption approved by FDA in September 1995, Vesta is studying the device as a non-surgical alternative to hysterectomy for the treatment of excessive menstrual bleeding (menorrhagia). Vesta plans to treat 180 patients at up to 12 clinical sites in the U.S.
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.